Products - Bladder cancer | Topic | NICE

Showing 11 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
13 May 2027
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
TAR-200 with cetrelimab for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6658]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Gemcitabine intravesical delivery system for treating recurrent high-risk papillary non-muscle-invasive bladder after BCG [ID6657]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC